Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 3, 2006, Pages 42-54

  Mensa, J ^a   Trilla, A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Acute exacerbations of chronic bronchitis; Chronic bronchitis; Chronic obstructive pulmonary disease; Fluoroquinolones; Respiratory tract infections; Review

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM; CEFACLOR; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NEUROLEPTIC AGENT; OFLOXACIN; ORAL ANTIDIABETIC AGENT; PENICILLIN G; QUINOLONE DERIVATIVE; SPARFLOXACIN; STEROID; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ACHILLES TENDON RUPTURE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BRONCHUS MUCUS; BRONCHUS OBSTRUCTION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; HEART ARRHYTHMIA; HUMAN; IN VIVO STUDY; LEUKOCYTE COUNT; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROBABILITY; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; SPUTUM ANALYSIS; TENDON INJURY; TREATMENT DURATION; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS);

EID: 33645802410     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01396.x     Document Type: Review

References (138)

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Care Medical 1995; 152: 77S-121S.
2. Hogg JC, Chu F, Utocaparch S et al. The nature of small airway obstruction in chronic pulmonary obstructive disease. New Engl J Med 2004; 350: 2645-2653.
3. Reid L. Measurement of the bronchial mucus gland layer: A diagnostic yard-stick for chronic bronchitis. Thorax 1960; 15: 132-141.
4. Saetta M, Turato G, Facchini FM et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1633-1639.
5. Wanner A. Clinical aspects of mucociliary transport. Am Rev Respir Dis 1977; 116: 73-125.
6. Matheson M, Benke G, Sim M et al. Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. Thorax 2005; 60: 645-651.
7. Barnes PJ. Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999; 54: 245-252.
8. Ito I, Nagai S, Hoshino Y et al. Risk and severity of COPD is associated with the group-specific component of serum globulin 1F allele. Chest 2004; 125: 63-70.
9. Cosio MJ. T-lymphocytes. In: Barnes, PJ, ed. Chronic Obstructive Pulmonary Disease. Boca Raton: Taylor & Francis Group, 2005; 205-252.
10. How JC. Role of latent viral infections in chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2001; 164: S71-S75.
11. Seemungal T, Harper R, Bhowmik A et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618-1623.
12. Rohde G, Wiethege A, Borg I et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: A case-control study. Thorax 2003; 58: 37-42.
13. Blasi F, Damato S, Cosentini R et al. Chlamydia pneumoniae and chronic bronchitis: Association with severity and bacterial clearance following treatment. Thorax 2002; 57: 672-676.
14. Wanner A, Salathe M, O'Riordan TG. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1966; 154: 1858-1902.
15. Knowles M, Boucher R. Mucus clearance as a primary innate defence mechanism for mammalian airways. J Clin Invest 2002; 109: 571-577.
16. Cole A, Dewan P, Ganz T. Innate antimicrobial activity of nasal secretions. Infect Inmunol 1999; 67: 3267-3275.
17. Zalacain R, Sobradillo V, Amilibia J et al. Predisposing factors to baterial colonization in chronic obstructive pulmonar disease. Eur Respir J 1999; 13: 343-348.
18. Monso E, Ruiz J, Rosell A et al. Bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: 1316-1320.
19. Rosell A, Monso E, Soler N et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 891-897.
20. Groenewegen K, Wouters E. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1 year prospective study. Respir Med 2003; 97: 770-777.
21. Groeneveld K, van Alphen Eijk P et al. Endogenous and exogenous re-infections by Haemophilus influenzae in patients with chronic obstructive airways disease: The effect of antibiotics treatment on persistence. J Infect Dis 1990; 161: 512-517.
22. Murphy T, Brauer A, Schiffmacher A, Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 266-272.
23. Takeda K, Akira S. Toll receptors and pathogen resistance. Cell Microbiol 2003; 5: 143-153.
24. Beeh KM, Kornmann O, Buhl R, Culppit SV, Giembycz MA, Barnes PJ. Nutrophil chemotactic activity of sputum from patients with COPD: Role of interleukin 8 and leukotriene B4. Chest 2003; 123: 1240-1247.
25. Tamino M, Betsuyaku T, Takeyabu K et al. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema. Thorax 2002; 57: 405-411.
26. Qiu Y, Zhu J, Bandi V et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 968-975.
27. Lordan JL, Bucchieri F, Richter A et al. Cooperative effects of Th2 cytoquines and allergen on normal and asthmatic bronchial epithelial cells. J Immunol 2002; 169: 407-414.
28. Sacco O, Romberger D, Rizzino A, Beckmann JD, Rennard SI, Spurzem JR. Spontaneous production of transforming growth factor-B2 by primary cultures of bronchial epithelial cells: Effects on cell behaviour in vitro. J Clin Invest 1992; 90: 1379-1385.
29. Vignola AM, Campbell AM, Chanez P et al. HLA-DR and ICAM-1 expression on bronchial epithelial cells in asthma and chronic bronchitis. Am Rev Respir Dis 1993; 148: 686-694.
30. Frick A, Joseph T, Pang L, Rabe A, Gme J, Look D. Haemophilus influenzae stimulates ICAM-1 expression on respiratory epithelial cells. J Immunol 2000; 164: 4185-4196.
31. Montuschi P, Kharitonov S, Ciabattoni G, Barnes JP. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003; 58: 585-588.
32. Crooks S, Bayley D, Hill S, Stockley R. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis. the role of leukotriene B4. Eur Respir J 2000; 15: 274-280.
33. Stockley R, O'Brien C, Pye A, Hill S. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1645.
34. Gompertz S, O'Brien C, Bayley D, Hill S, Stockley R. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001; 17: 1112-1119.
35. MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 2001; 7: 55-62.
36. Gadek J. Adverse effects of neutrophils on the lung. Am J Med 1992; 92 (Suppl. 6A): 27S-31S.
37. Nadel JA. Role of mast cell and neutrophil proteases in airway secretion. Am Rev Respir Dis 1991; 144: S48-S51.
38. Nelson S, Summer W, Mason C. The role of the inflammatory response in chronic bronchitis: Therapeutic implications. Seminars Respiratory Infections 2000; 15: 24-31.
39. Hill A, Gompertz S, Stockley R. Factors influencing airway inflammation in chronic obstructive pulmonary disease. Thorax 2000; 55: 970-977.
40. Barnes PJ, Shapiro SD, Pawels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688.
41. Zinder GL. Understanding inflammation in chronic obstructive pulmonary disease: The process begins. Am J Respir Crit Care Med 2003; 167: 1045-1046
42. Wilkinson T, Patel I, Wilks M, Donaldson G, Wedzicha J. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1090-1095.
43. Donaldson G, Seemungal T, Bhowmik A, Wedzicha J. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
44. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard B. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk factors of chronic obstrucitve pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1008-1011.
45. Stanescu D, Sanna A, Veriter C et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51: 267-271.
46. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999; 160: S49-S52.
47. Petty T. COPD in perspective. Chest 2002; 121: 116S-120S.
48. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodelling. Am J Respir Cell Mol Biol 2003; 28: 12-14.
49. Cole P, Wilson R. Host-microbial interrelationships in respiratory infections. Chest 1989; 95: 217S-221S.
50. Hill A, Campbell E, Hill S, Bayley D, Stockley R. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109: 288-295.
51. Sethi S, Muscarella K, Evans N, Klingman K, Grant B, Murphy T. Airway inflammation and aetiology of acute exacerbations of chronic bronchitis. Chest 2000; 118: 1557-1565.
52. Stefano A, Capelli A, Lusuardi M et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277-1285.
53. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease Morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535.
54. Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD. a multiple logistic regression analysis. The EOLO Study Group Respiration 2000; 65: 495-501.
55. Fuso L, Incalzi R, Pistelli R et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98: 272-277.
56. Bandi V, Jakubowycz M, Kinyon C et al. Infectious exacerbations of chronic obstrucitve pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microb 2003; 37: 69-75.
57. Anzueto A, Neiderman M. Diagnosis and treatment of rhinovirus respiratory infections. Chest 2003; 123: 1664-1672.
58. Greenberg S, Allen M, Wilson J, Atmar R. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 167-172.
59. Hamelin M, Côte S, Laforge J et al. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41: 498-502.
60. Groenelved K, Van Alphen L, Eijk P, Visschers G, Jansen H, Zanen H. Endogenous and exogenous reinfections by Haemophilus influenzae in patients with chronic obstructive pulmonary disease: The effect of antibiotic treatment on persistence. J Infect Dis 1990; 161: 512-517.
61. Yi K, Sethi S, Murphy T. Human immune response to nontypeable Haemophilus influenzae in chronic bronchitis. J Infect Dis 1997; 176: 1247-1252.
62. Sethi S, Evans N, Brydon R, Grant J, Murphy T. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471.
63. Sethi S, Wrona C, Grant B, Murphy T. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 448-453.
64. Bakri F, Brauer A, Sethi S, Murphy T. Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease. J Infect Dis 2002; 185: 632-640.
65. Chin C, Manzel L, Lehman E et al. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005; 172: 85-91.
66. Murphy T. Haemophilus influenzae in chronic bronchitis. Seminars Respiratory Infections 2000; 15: 41-51.
67. Groeneveld K, Van Alphen L, Eijk P, Jansen H, Zanen H. Changes in outer membrane proteins of nontypable Haemophilus influenzae in patients with chronic obstructive pulmonary disease. J Infect Dis 1988; 158: 360-363.
68. Beaty CD, Grayston JT, Wang SP, Kuo CC, Reto CS, Martin TR. Chlamydia pneumoniae, strain Twar, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 144: 1408-1410.
69. Blasi F, Legnani D, Lombardo VM et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993; 6: 19-22.
70. Lieberman D, Yaakov M, Lazarovich Z, Boldur B. Chlamydia pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease: Analysis of 250 hospitalizations. Eur J Clin Microbiol Infect Dis 2001; 20: 698-704.
71. Seemungal TAR, Wedzicha JA, MacCllum PK, Johnston SL, Lambert PA. Chlamydia pneumoniae and COPD exacerbations. Thorax 2002; 57: 1087-1088.
72. Patel I, Seemungal T, Wilks M, Lloyd-Owen S, Donaldson G, Wedzicha J. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
73. Dewan N, Rafique S, Kanwar B et al. Acute exacerbation of COPD. Chest 2000; 117: 662-666.
74. Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Eur Respir J 2001; 17: 928-933.
75. Donaldson G, Seemungal T, Patel I, Lloyd-Owen S, Wilkinson T, Wedzicha J. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003; 22: 931-936.
76. Seemungal T, Donaldson G, Bhowmik A, Jeffries D, Wedzicha J. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613.
77. Murphy T, Brauer A, Grant B, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 195-199.
78. Mobbs KJ, Van Saene H, Sunderland D, Davies P. Oropharyngeal gram-negative bacillary carriage in chronic obstructive pulmonary disease: Relation to severity of disease. Respir Med 1999; 93: 540-545.
79. Eller J, Ede A, Schaberg T, Niederman M, Mauch H, Lode H. Infective exacerbations of chronic bronchitis. Chest 1998; 113: 1542-1548.
80. Soler N, Torres A, Ewig S et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-1505.
81. Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40-46.
82. Murphy T, Sethi S, Kligman K, Brueggemann A, Doern G. Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: Implications for antibiotic therapy. J Infect Dis 1999; 180: 404-409.
83. Shakhnovich E, King S, Weiser J. Neuraminidase expressed by Streptococcus pneumoniae desialylates the lipopolysaccharide of Neisseria meningitidis and Haemophilus influenzae: A paradigm for interbacterial competition among pathogens of the human respiratory tract. Infection Inmunity 2002; 70: 7161-7164.
84. Van der Valk P, Monninkhof E, Van der Palen J, Zielhuis G, Van Herwaarden C, Hendrix R. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2004; 39: 980-986.
85. Elmes P, Fletcher C, Dutton A. Prophylactic use of oxytetracicline for exacerbations of chronic bronchitis. Br Med J 1957; 2: 1272-1275.
86. Elmes P, King T, Langlands J et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br Med J 1965; 2: 904-908.
87. Nicotra M, Rivera M, Awe A. Antibiotic therapy of acute exacerbations of chronic bronchitis. Ann Intern Med 1982; 97: 18-21.
88. Joergensen A, Coolidge J, Pedersen P et al. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. Scand J Prim Health Care 1992; 10: 7-11.
89. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. JAMA 1995; 273: 957-960.
90. Anthonisen N, Manfreda J, Warren C, Hershfield E, Harding G, Nelson N. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 204.
91. Allegra L, Blasi F, Bernardi B, Cosentini R, Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: A re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther 2001; 14: 149-155.
92. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: A randomised placebo-controlled trial. Lancet 2001; 358: 2020-2025.
93. Wilkinson T, Donaldson G, Hurst J, Seemungal T, Wedzicha J. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-1303.
94. MacGowan A, Wootton M, Holt H. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother 1999; 43: 345-349.
95. Jacobs; Felmingham D, Appelbaum P, Grüneberg R and the Alexander Project Group. The Alexander Project Group 1998-2000: Susceptibility of pathogens isolated from community acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-246
96. Pfaller M, Ehrhardt A, Jones R. Frequency of pathogen ocurrence and antimicrobial susceptibility among community-acquired respiratory surveillance program study: Microbiology from the medical office practice environment. Am J Med 2001; 111: 4S-11S.
97. Gotfried M, Danziger L, Rodvold K. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjets. Chest 2001; 119: 1114-1122.
98. Soman A, Honeybourne D, Anrews J et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a simple 400mg oral dose in patients undergoing fibreoptic bronchoscopy. J Antimicrob Chemother 1999; 44: 835-838.
99. Bosselli E, Breilh D, Rimmele T et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med 2005; 33: 104-109.
100. Honeybourne B, Bannergee D, Andrews J et al. Concentrations of gatifloxacin in plasma and pulmonary compartments following a simple 400mg oral dose in patients undergoing fibreoptic bronchoscopy. J Antimicrob Chemother 2001; 48: 63-66.
101. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108: 43S-52S.
102. Koizumi F, Ohnishi A, Takemura H, Okubo S, Kagami T, Tanaka T. Effective monitoring of concentrations of ofloxacino in saliva of patients with chronic respiratory tract infections. Antimicrob Agents Chemother 1994; 38: 1140-1143.
103. Ambrose P, Grasela D, Grasela T et al. Pharmacodynamics of fluorquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45: 2793-2797.
104. Lister P, Sanders C. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999; 43: 79-86.
105. Forrest A, Nix D, Ballow C et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993 37 1073-1081
106. Davies T, Goldschmidt R, Pfleger S et al. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother 2003; 52: 168-175.
107. Anderson K, Tan J, File T, DiPersio J, Willey B, Low D. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003; 37: 376-381.
108. De la Campa A, Ferrandiz M, Tubau F, Pallarés R, Manresa F, Liñares J. Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis. Antimicrob Agents Chemother 2003; 47: 1419-1422.
109. Weis K, Restieri C, Gauthier R et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis 2001; 33: 517-522.
110. Perez-Trallero E, Marimon J, Gonzalez A et al. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41: 560-564.
111. Doern G, Heilmann K, Huynh K et al. Antimicrobial resistance among clinical isolates of Streptoccocus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-95. Antimicrob Agents Chemother 2001; 45: 1721-1729.
112. Thornsberry C, Sahm D. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catharralis in the United States: Results from the TRUST surveillance program 1999-2000. Clin Infect Dis 2004; 34 (Suppl. 1): 4S-16S.
113. Karchmer A. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - an update. Clin Infect Dis 2004; 39 (Suppl. 3): S142-S150.
114. Zhanel G, Palatnick L, Nichol K et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997-2002. Antimicrob Agents Chemother 2003; 47: 1867-1874.
115. Oteo J, Alos I, Gómez-Garces J. Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: A multicentre surveillance study. J Antimicrob Chemother 2001; 47: 215-218.
116. Buxbaum A, Straschil U, Moser C et al. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. J Antimicrob Chemother 1999; 43: 13-18.
117. Glatz K, Szabo D, Szabo G et al. Emergence of extremely high penicillin and cefotaxime resistance and high-level levoflocaxin resistance in clinical isolates of Streptococcus pneumoniae isolates in Hungary. J Antimicrob Chemother 2001; 48: 215-218.
118. Biedenbach D, Jones R. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America). Diagn Microbiol Infect Dis 2000; 36: 255-259.
119. Rennie R, Ibrahim K. Antimicrobial resistance in Haemophilus influenzae: How can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on date from the TARGETed surveillance program. Clin Infec Dis 2005; 41 (Suppl. 4): S234-S238.
120. Chodosh S, Schreurs A, Siami G et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998; 27: 730-738.
121. Chodosh S, McCarty J, Farkas S et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998; 27: 722-729.
122. Grassi C, Salvatori E, Rosignoli T, Dionisio P. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis. Respiration 2002; 69: 217-222.
123. Langan C, Zuck P, Vogel F et al. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 515-523.
124. Masterton R, Burley C. Randomized, double-blind study comnparintg 5 and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2001; 18: 503-512.
125. Amsden G, Baird I, Simon S, Tredway G. Efficacy and safety of azitrhomycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123: 772-777.
126. Wilson R, Schentag J, Ball P, Mandell L, for the 068a Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002; 24: 639-652.
127. Sethi S, Fogarty B, Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir Med 2004; 98: 697-707.
128. Gotfried M, DeAbate A, Fogarty C, Mathew C, Sokol W. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Therapeutics 2001; 23: 97-107.
129. Soler M, Lode H, Baldwin R et al. Randomised double-blind comparison of oral gatifloxacin and Co-amoxiclav for acute exacerbation of chronic bronchitis. Eur J Clin Microbiol Infect Dis 2003; 22: 144-150.
130. Wilson R, Kubin R, Ballin I et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-503.
131. Chodosh S, Deabate C, Haversrtock D, Aneiro L, Church D. Short-course moxifloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Respir Med 2000; 94: 18-27.
132. DeAbate C, Mathew C, Warner J, Heyd A, Church D. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients wit acute exacerbation of chronic bronchitis. Respir Med 2000; 94: 1029-1037.
133. Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-964.
134. White A, Gompertz S, Bayley D et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680-685.
135. Khaliq Y, Zhanel G. Fluoroquinolone-associated tendinopathy: A critical review of the literature. Clin Infect Dis 2003; 36: 1404-1410.
136. Noel J, Natarajan J, Chien S et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003; 73: 292-303.
137. Menzies D, Dorsainvil P, Cunha B et al. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycaemic agents. Am J Med 2002; 113: 232-234.
138. Bouza E, Garcia-Garrote F, Cercenado E, Marín M, Díaz M. Pseudomonas aeruginosa: A survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group. Antimicrob Agents Chemother 1999; 43: 9